recording

POSTERS ESMO 2024

esmo

Tumores del sistema nervioso central

Jesús Gustavo Yaringaño Cerna

acceso

Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of Glioblastoma (GBM).

  • Jesús Gustavo Yaringaño Cerna

    Hospital Universitario Vall d’Hebron. Barcelona
Juán Manuel Sepúlveda Sánchez

acceso

Tetrahidrocannabinol (THC) / Cannabidiol (CBD) Oral Solution in Combination with Temozolomide (TMZ) and Radiotherapy (RT) in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO-1601 Trial.

  • Juán Manuel Sepúlveda Sánchez

    Hospital Universitario 12 de Octubre. Madrid

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON